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1. Introduction
Volatile organic compounds (VOCs) are produced 
in the body as a result of various metabolic processes 
and endogenous VOC analysis in the breath has been 
proposed as a potential diagnostic tool in human 
disease. Breath analysis has attracted clinical and 
scientific attention as a potential means for delivering 
non-invasive, real-time rapid screening and diagnosis 
of complex diseases. Recent overviews of the field 
are provided in a book published in 2014 [1] and in 
numerous review papers [2–6].
Breath VOCs have been measured in patients with 
liver disease in a number of studies [7–21] and several 
VOCs have been suggested as biomarkers for cirrho-
sis. In particular, sulphur compounds have been sug-
gested as being associated with liver disease and are 
responsible for the characteristic odour of patient’s 
breath called Foetor Hepaticus [19, 22]. Previous work 
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Abstract
Breath samples were taken from 31 patients with liver disease and 30 controls in a clinical setting 
and proton transfer reaction quadrupole mass spectrometry (PTR-Quad-MS) used to measure the 
concentration of volatile organic compounds (VOCs). All patients had cirrhosis of various etiologies, 
with some also suffering from hepatocellular cancer (HCC) and/or hepatic encephalopathy (HE). 
Breath limonene was higher in patients with No-HCC than with HCC, median (lower/upper 
quartile) 14.2 (7.2/60.1) versus 3.6 (2.0/13.7) and 1.5 (1.1/2.3) nmol mol−1 in controls. This may 
reflect disease severity, as those with No-HCC had significantly higher UKELD (United Kingdom 
model for End stage Liver Disease) scores. Patients with HE were categorized as having HE symptoms 
presently, having a history but no current symptoms and having neither history nor current 
symptoms. Breath limonene in these groups was median (lower/upper quartile) 46.0 (14.0/103),  
4.2 (2.6/6.4) and 7.2 (2.0/19.1) nmol mol−1, respectively. The higher concentration of limonene 
in those with current symptoms of HE than with a history but no current symptoms cannot be 
explained by disease severity as their UKELD scores were not significantly different. Longitudinal 
data from two patients admitted to hospital with HE show a large intra-subject variation in breath 
limonene, median (range) 18 (10–44) and 42 (32–58) nmol mol−1.
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has included patients with various etiologies, different 
sampling methods and different analytical methods. It 
is, therefore, difficult to compare results. There is some 
agreement as to which potential biomarkers are associ-
ated with liver disease, but not all studies find the same 
volatile markers. As previously reported [7], these issues 
were addressed by conducting a two phase biomarker 
discovery study. Limonene, methanol and 2-pentanone 
were identified as biomarkers of liver cirrhosis. These 
VOCs not only discriminated cases from controls but 
were also significantly different before and after liver 
transplantation in a sub-group of patients who had 
received a transplant.
Pilot data [23] was obtained by our group prior 
to the published study from patients in out-patient 
clinic. Twelve had cirrhosis or fibrosis, four had neu-
roendocrine disease with liver tumours and five 
had well-functioning graft livers following previous 
liver transplants due to Hepatitis C virus. This study 
found that a monoterpene, which was assumed to be 
limonene, had elevated concentrations in the breath 
of patients with cirrhosis, and in particular, those with 
hepatic encephalopathy (HE). Limonene in the breath 
of patients with liver cirrhosis has been observed in 
two other studies using GC-MS [9, 10] and tenta-
tively identified in a proto n transfer reaction—time of 
flight-mass spectrometric (PTR-TOF-MS) study [13]. 
Limonene is a monoterpene of dietary origin, typically 
found in citrus fruits but also naturally occurring in 
many vegetables. There is no evidence to suggest that 
it can be produced in the human body. It is used in the 
food and drink industry to give a citrus flavor and in 
perfumes and air fresheners. As such, it is a ubiquitous 
exogenous compound and it would be difficult to avoid 
in the diet in general. Limonene is metabolized in the 
liver by the P450 enzymes CYP2C9 and CYP2C19 [24] 
to the metabolites perillyl alcohol, trans-carveol and 
trans-isopiperitenol. It has been noted that levels of the 
enzyme CYP2C19 are reduced in patients with cirrhosis 
and, that levels inversely correlate with severity of cir-
rhosis [25]. This presents the possibility that elevated 
levels of limonene in the body may be associated with 
liver disease owing to a reduced ability of the liver to 
produce the appropriate metabolic enzymes, as has 
already been noted [13].
The present work will discuss these results further in 
respect to HE, a co-morbidity of advanced liver cirrho-
sis. Comparisons of cirrhosis with and without hepa-
tocellular cancer (HCC) and HE will be shown. Results 
of longitudinal data on patients with HE to examine 
intra-individual variation in these three VOCs of inter-
est will also be shown.
HE is a spectrum of neuropsychiatric abnormal-
ity associated with liver dysfunction. Symptoms vary 
in severity depending on the stage of the illness and 
include confusion, lethargy, sleep disturbance, person-
ality change and cognitive impairment. In its extreme 
form, it can lead to coma and even death [26]. Overt 
HE (OHE) can be diagnosed clinically, usually using 
a scoring system such as the West-Haven criteria, and 
can be episodic or persistent. HE can affect the patient’s 
mental functioning intermittently [27], so it is possible 
for them to pass a neurological test on the day of the 
examination, while still suffering from symptoms at 
other times.
Minimal HE (MHE) is difficult to diagnose and 
requires specialized testing. It is possible for patients to 
be suffering from undiagnosed MHE [28]. There is no 
gold standard for the diagnosis of HE and many scor-
ing systems have been criticized for lack of objectivity 
[28]. Current recommendations [29] include using the 
clinical HE staging scale (CHESS) [30], the HE scor-
ing algorightm (HESA) [31] or modified orientation 
log (MOD) to refine the West-Haven criteria but their 
widespread use has yet to be adopted.
Estimates of the incidence of MHE range from 20% 
to 84% of cirrhotic patients, depending on which test-
ing methods are used [27]. HE not only degrades qual-
ity of life, but it means a poorer prognosis for the patient 
[32]. HE is thought to be caused by the action of neuro-
toxic substances including ammonia and manganese, 
which are usually metabolised by the liver, persisting in 
elevated concentrations. These toxins can then cause 
glutamine induced changes in astrocytes that lead to the 
clinical manifestations of HE [33, 34]. Usual treatment 
is through the use of laxatives and antibiotics which act 
to prevent the accumulation of toxins. In the advanced 
stages, patients must be admitted to hospital for man-
agement of episodes of OHE.
Breath analysis for HE has been investigated pre-
viously in two other pilot studies which used GC-MS 
in patients with cirrhosis [20, 35], but neither of these 
reported limonene as a marker for HE. One pilot study 
investigated HE using an e-nose [36], but this technique 
is unable to specify exactly which VOCs are responsible 
for the discrimination so it is not possible to determine 
whether it is based on limonene.
2. Methods
2.1. Patients, controls and hospital room air
Patients were recruited at the University Hospital 
Birmingham from either the transplant assessment 
clinic or in wards after being admitted with HE. The 
regional ethics committee of Camden and Islington, 
London approved this study (REC reference: 13/
LO/0952). Written informed consent was obtained 
from each volunteer.
Thirty-one patients suffering from liver disease 
participated in the pre-transplant measurements (F/M 
8/23, mean age 55 years, min–max 27–71 years). There 
were a number of etiologies and 11 patients had more 
than one condition. Full details of the patients and their 
diagnoses are given in our earlier publication which 
reported volatiles associated with liver cirrhosis.
For the longitudinal data, two patients were 
recruited having been admitted as in-patients suffer-
ing from HE. Patient M1 was a 54 years old male with a 
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primary diagnosis of alcoholic liver disease (ALD). He 
gave four breath samples during an admission for HE 
before his liver transplant, then three further samples 
after transplant. Patient M15 was also a 54 years old 
male with a primary diagnosis of ALD. He gave breath 
samples on seven different days during an admission 
for HE. He did not receive a transplant so gave no post-
transplant samples.
For 28 pre-transplant measurements, breath sam-
ples from the patients’ companions were taken. For the 
other three, two came alone to clinic and the other’s 
companion declined to take part. Two additional con-
trols were therefore recruited, one was a ward nurse 
and the other was a visitor to the hospital in ITU. These 
controls, while not related to the patient, had been in 
the same room for several hours prior to sampling so 
that confounding factors associated with any volatiles 
present in the room environment could be taken into 
consideration. In total 30 controls (F:M 23:7, mean age 
44 years, min–max 20–75 years) took part in the study. 
The larger number of females in the control group arose 
because the majority of patients were men and often 
attended the clinic with their wives. While this means the 
control group is not ideally matched, there is no consist-
ent evidence of dependences of volatile breath composi-
tion on sex [1, 37]. In confirmation of this, no correlation 
was found between sex and VOCs in either our control 
or patient groups. It was considered that inhaled VOCs 
have a greater potential to confound biomarker discov-
ery. As the majority of the companions were living with 
the patients, they provided an ideal control for exposure 
of exogenous volatiles in the home environment. VOCs 
inhaled at home, or in transit, may well still be present in 
breath for hours or days after inhalation; the biological 
half-life of inhaled VOCs are not well known and in any 
case may be patient-specific [38].
All study subjects were asked to complete a detailed 
questionnaire which included details on their home 
environment, diet, smoking status, health and medi-
cations. Participants were asked if they had consumed 
fruit, fruit juices and fruit-flavoured drinks as a nor-
mal part of their diet, and, if so, to provide details on 
quanti ty and how long before the breath sampling these 
had been consumed.
Hospital room air was collected every time breath 
samples were taken so that any exogenous volatiles, 
such as isopropanol coming from hand gels, resulting 
in product ions at m/z 43 and m/z 61, could be taken 
into consideration. There are fewer room air samples 
than patient-control pairs because the same room was 
used for consecutive patient-control pairs on the same 
day in some cases.
Diagnosis of HCC was based on previous invest-
igations including radiology and histology. For analy-
sis of HCC, the groupings are HCC (N  =  10): those 
with at least one hepatocellular tumour, and No-HCC 
(N  =  21): those with no hepatocellular tumours. HE 
status was assessed both from clinical diagnosis using 
the West Haven criteria and also from questioning of the 
patient and the relative with whom they were attend-
ing clinic. Patients and relatives were questioned as to 
whether the patient was suffering from any symptoms 
of HE at the present time and were classed as having HE 
at the present time if they answered yes. Some patients 
and relatives reported having had HE in the past, some-
times following a trigger such as an infection, but that 
the patient had recovered and was not symptomatic 
on the day of the breath sample. These patients were 
classed as having a history but not currently suffering. 
The final group of patients had never had HE and did 
not have symptoms on the day of sampling according 
to their medical records and their own and their com-
panions’ assessment of their mental function. These 
patients are classed as ‘No-HE’. For analysis of HE, the 
grouping are: 1. HE-now: suffering symptoms of HE 
on the day the breath samples were taken (N  =  11); 
2. History-HE: had suffered from HE in the past but 
were not suffering symptoms on the day of sampling 
(N  =  7), and 3. No-HE: those who were not suffering 
symptoms on the day of sampling, nor had any history 
of HE (N  =  11). All patients were ambulatory and were 
seen in clinic, apart from four who had been admitted 
to hospital for HE, one of whom had acute liver failure. 
Only one patient (ID code M15) had HE above grade 
2. In the No-HE and History-HE groups, no patients 
were taking medication for HE. One patient in each of 
these two groups was taking lactulose, but in each case 
this was for constipation, not for symptoms of HE. Of 
the 11 HE-now patients, eight were taking medication 
for HE: three were on lactulose and rifaximin, one on 
rifaximin only and four on lactulose only.
2.2. Breath sampling protocol
There is no agreed standard for the collection of breath 
for volatile analysis, and uncontrolled breath sampling 
has been shown to be unreliable [39, 40]. Therefore, 
capnography controlled sampling was used to collect 
only the alveolar phase of the breath. Subjects were in 
a relaxed state throughout the measurements and were 
either in a seated or recumbent position. They were 
asked to breathe normally into a gas tight respiratory 
system (Intersurgical Limited) containing an in-line 
CO2 mainstream sensor connected to a fast-time 
response capnometer (Capnogard 1265 Novametrix 
Medical Systems Inc.). A 100 ml glass syringe (Sigma-
Aldrich) was coupled to the tubing using a 3-way luer-
lock stopcock (Braun Medical Limited). When the 
alveolar plateau on the capnograph was observed, a 
breath sample was manually drawn from the subject’s 
breath stream into the syringe. Three to four alveolar 
breath samples were collected for each 100 ml syringe, 
and four replicates of these were taken for each subject. 
Glass syringes were used, because our tests showed 
that they have no contaminating volatiles. Figure 1 
schematically shows the sampling system used.
After collection, the syringes were sealed using the 
luer lock fitting. They were transported from hospital 
to laboratory (a 10 min outdoor walk) in an opaque 
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 storage box. Once at the laboratory, the syringes were 
placed inside an incubator set at 40 °C.
All samples were mass spectrometrically analyzed 
within 2 h of collection. For the measurements, syringes 
were taken out of the incubator and immediately 
placed into a purpose designed heating bag (Infroheat, 
 Wolverhampton) maintained at a constant temper-
ature of 40 °C in order to limit condensation, which 
could otherwise lead to volatile loss [40]. The luer stop-
cock was coupled to a Swagelok fitting and connected 
directly to the inlet of the analytical device, a proton 
transfer reaction mass spectrometer (PTR-MS). The 
inlet flow was set at 10–15 ml min−1 and the drift tube 
and inlet lines were maintained at 45 °C. The syringes 
are gas tight and have minimal friction such that atmos-
pheric pressure is sufficient to push the plunger in 
smoothly so that the breath sample is being drawn into 
the instrument at a constant flow.
2.3. Analytical measurements
PTR-MS is a platform technology designed to detect 
low concentrations of volatiles (less than parts per 
billion by volume). Hence it has found use in many 
analytical applications ranging from drug detection 
through to industrial pollution [1, 41–44]. Details of 
the instrument used, a PTR-Quad-MS (IONICON 
Analytik GmbH), and how it operates are described in 
detail in the literature [1, 40, 41]. In brief, it exploits 
the reactions of protonated water with neutral 
volatiles (M), usually leading to a protonated parent 
(MH+). If dissociative proton transfer occurs then it 
is not extensive in terms of the number of resulting 
product ions. Operational parameters used for this 
investigation were those previously reported [45, 46]. 
Namely, the drift-tube was maintained at a pressure of 
2.07  ±  0.01 mbar and temperature of 45  ±  1 °C. The 
voltage across the drift-tube was set at 600 V, which is 
sufficiently high to reduce water clustering to reagent 
and product ions by collision induced dissociation.
A m/z range of 20–200 amu was scanned with a 
dwell time of 0.5 s per atomic mass unit. Mass spectra 
of the breath samples were recorded from the average 
of three cycles for each of the four syringes, for every 
participant. These four spectra were averaged to pro-
vide one data set for each subject with the uncertainty 
expressed as the standard error of the mean for the four 
syringes.
The intensities of the product ion(s) associated 
with a given volatile were converted from nor malized 
counts per second (cps) to volume mixing ratios 
(VMR) in units of nmol mol−1. Normalisation was to 
50 million cps of the sum of the area under the peak 
of the H3O+ and the (H3O+) · (H2O) ions. Conver-
sion to VMR was by use of a standard procedure that 
relies on a calculated, compound-specific, collisional 
reaction rate coefficient, determined using the effec-
tive translational temperature of the reagent ions [1]. It 
should be noted that PTR-Quad-MS has a mass resolu-
tion of approximately 1 amu so it is possible that other 
compounds or fragments could contribute to observed 
peaks.
To help identify product ions, pure samples of key 
volatiles were individually measured using PTR-MS to 
establish the m/z values of the product ions.
2.3.1. Statistical analyses
The data sets for each volatile of interest were assessed 
using a Shapiro–Wilks test and were found not to be 
normally distributed so non-parametric tests were 
used. IBM SPSS version 22 was used for all statistical 
analysis. Mann–Whitney U-tests determined which 
m/z values differed between the patients and controls in 
the original study, and to assess whether concentrations 
of volatiles were significantly different between HCC 
with non-HCC patients. A Kruskal–Wallis one way 
analysis of variance was used to compare the HE-now, 
History-HE and No-HE groups. All tests were done 
using a significance level of 0.95.
Figure 1. Schematic of the breath sampling device. Breath samples are only drawn into the glass syringe once the capnograph shows 
that the alveolar phase of the exhaled breath has been reached. Typically 3–4 breaths are needed to fill a 100 ml syringe.
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3. Results and discussion
3.1. Case control study
As previously reported [7], differences between patients 
and controls were found for four mass spectral peaks: 
m/z 33, m/z 81, m/z 87 and m/z 137. Peaks at m/z 81 and 
m/z 137 result from limonene; the protonated parent is 
at 137 and m/z 81 is a fragment ion (C6H9) [47, 48]. The 
area under the peaks for both m/z 81 and m/z 137 were 
summed and used to determine the concentration of 
limonene in the breath samples. PTR-MS is unable to 
differentiate isomers, and there is a possibility that other 
monoterpenes could have contributed to these peaks. 
However, previous work in humans has indicated that 
limonene is the most abundant monoterpene in human 
breath and blood [49]. GC-MS confirmation was 
performed with one of the breath samples to confirm 
the presence of limonene by colleagues at the Max 
Planck Institute in Mainz, Germany. The methodology 
has been previously reported [50, 51]. Limonene has 
also been shown to be elevated in the breath of patients 
with liver disease in other studies [10, 13].
The patient group has been further subdivided into 
those with and without hepatocellular cancer (HCC 
and No-HCC, respectively. Box plots of limonene, 
methanol (m/z 33) and 2-pentanone (m/z 87) for 
patients with and without HCC, controls and room air 
are shown in figure 2. Figures for mean, (lower quar-
tile (LQ)/upper quartile (UQ)) are given in the figure. 
There is a difference between patients with and without 
HCC only for limonene, with a Mann–Whitney U score 
of significance p  =  0.015.
Figure 3 shows comparisons for the groups 
No-HE, History-HE, HE-now, controls and room air. 
Compariso n of the three patient groups revealed that 
only one VOC, limonene, was able to successfully differ-
entiate the groups with a Kruskall–Wallis score of sig-
nificance p  =  0.001. Figure 3 shows a clear difference 
between HE-now and History-HE. For No-HE, there 
is overlap with the HE-now group, but this is highly 
skewed by just three patients.
It was conjectured that the difference in means 
between breath limonene in the No-HCC versus HCC 
groups may be a reflection of severity of cirrhosis. Often 
patients are considered for transplant on the basis of the 
presence of a hepatocellular tumour while the rest of the 
liver is still compensating adequately. This conjecture is 
supported by analysis of the UKELD (United Kingdom 
model for End-stage Liver Disease) score for the groups. 
UKELD is a scoring algorithm which combines a selec-
tion of clinical chemistry values and gives a prediction 
of 1 year mortality [52]. It is used to select patients for 
Figure 2. Boxplots showing in units of nmol mol−1 lower quartile (LQ), median (Med), and upper quartile (UQ) calculated volume 
mixing ratios (VMRs) for (a) limonene, (b) methanol and (c) 2-pentanone for 21 patients with liver cirrhosis without HCC  
(No-HCC), 10 patients with cirrhosis and HCC (HCC), 30 controls and room air. Whiskers are 1.5 times the inter-quartile range 
and outliers are depicted by a star.
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transplant in the United Kingdom and patients are 
usually considered for transplant when their UKELD 
score is  >49, unless there is an additional indication 
for transplant such as HCC. The mean (range) of the 
UKELD score for the No-HCC and HCC groups is 54 
(48–63) and 49 (43–56), respectively. These are signifi-
cantly different (Mann–Whitney p  =  0.002). A similar 
analysis was done for the HE classifications to deter-
mine whether patients in the HE-now group had more 
severe disease. UKELD scores for the three groups were 
49 (43–57) for No-HE, 53 (46–63) for History-HE and 
55 (51–62) for HE-now. There is no significant differ-
ence between the UKELD scores for the History-HE and 
HE-now groups (Mann–Whitney p  =  0.21), but there 
is a significant difference between the No-HE groups 
and the HE-now groups (Mann–Whitney p  =  0.001). 
It is perhaps not surprising that the group which has 
never experienced HE has a lower UKELD score than 
the group which was suffering symptoms at the time 
of sampling. However, the large difference in limonene 
between the History-HE group and the HE-now group 
cannot be explained by a difference in severity as judged 
by UKELD score. Overall, as previously reported [7], 
there is no correlation between the concentration of 
breath limonene and UKELD score. A prospective 
observational multicentre study of 1348 patients in 
29 liver units in eight European countries was recently 
undertaken to investigate risk factors for the develop-
ment of HE and assess survival in patients with liver 
cirrhosis [53]. This found that previous HE was the most 
important risk factor for the development of HE, with 
a poor relationship between traditional precipitating 
factors such as bacterial infections, active alcoholism 
or gastrointestinal haemorrhage. Our present study 
has found that limonene is able to distinguish between 
 History-HE and HE-now groups, which presents the pos-
sibility of a screening or monitoring tool to enable target-
ing of prophylactic therapies in at-risk populations.
As previously reported [7], there was no association 
between self-reported consumption of fruit/fruit juice 
Figure 3. Boxplots showing in units of nmol mol−1 lower quartile (LQ), median (Med) and upper quartile (UQ) calculated volume 
mixing ratios (VMRs) for (a) limonene, (b) methanol and (c) 2-pentanone for 11 patients without HE (No HE), 8 patients who 
have a history of HE but are not showing symptoms on the day of sampling (History HE), 12 patients who were suffering symptoms 
of HE on the day of sampling (HE-now), 30 controls and room air. Whiskers are 1.5 times the inter-quartile range and outliers are 
depicted by a star.
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and elevated breath limonene. Studies by us (unpub-
lished) have shown that in normal healthy people, con-
sumption of pure, concentrated orange juice is followed 
by a small increase in breath limonene which returns 
to baseline within half an hour. There is nothing in the 
diet or previous 24 h diet of the patients which would 
explain elevated breath limonene.
Khalid et al suggested isothiocyanato-cyclohexane 
as indicating the presence of HE, and methyl vinyl 
ketone as indicating absence of HE within a group of 
alcoholic cirrhotics [35]. They used a presence/absence 
analysis in which absolute concentrations were not 
measured; rather only the presence or absence of a com-
pound above three times the signal to noise ratio was 
compared across groups. Using this analysis, our previ-
ous results would not have shown a difference between 
cases and controls because limonene was also observed 
in controls, albeit at very low concentrations. Limonene 
has also been found in the blood and in the emissions 
from skin of healthy volunteers, and can be consid-
ered a normal volatile emission from healthy humans 
[54, 55]. A previous study using GC-MS to examine 
the normal volatile constituents of human breath 
reported limonene in the venous blood and breath of 
all 28  subjects [49]. The mean (range) concentration 
in breath was 1.46 ppbv (0.27–7.42), which is similar 
to our findings.
To our knowledge, Vollnberg et al [20] remains, 
until now, a conference abstract rather than a full paper 
so insufficient details are known to make a compariso n, 
but they noted acetoin (3-hydroxybutanone) and 
2-pentanone as having predictive utility for HE [20]. 
The present study has found 2-pentanone as predic-
tive for the presence of cirrhosis versus controls, but 
did not find a difference between those with and with-
out HE. Participants had been asked to indicate when 
they last had something to eat or drink, but there was 
no  association with time since last meal and concentra-
tion of 2-pentanone. Acetoin would give a prot onated 
parent peak at m/z 89. In our initial case-control com-
parison, m/z 89 was significantly different between 
patients and controls. It did not, however, show a dif-
ference between patients pre- and post-transplant so it 
was discounted as being a useful diagnostic volatile for 
liver cirrhosis. Figure 4 shows the box plot for group-
ings of HE status for m/z 89. Only normalized counts 
per second are shown as we are not confident about 
assigning an identity to this peak. The HE-now group 
is significantly different from the other groups, but the 
variation in room air is large and it overlaps with all 
other groups. An examination of the 12 patients who 
had a transplant shows that the concentration of m/z 89 
in patients with and without HE is not significantly dif-
ferent. It is important to bear in mind that isomeric and 
isobaric compounds cannot be distinguished in our 
system and a signal from acetoin may be confounded 
by the presence of another volatile which produced a 
product ion at the same m/z.
3.2. Longitudinal study
Two patients (ID codes M1 and M15) who had been 
admitted suffering with HE were followed over the 
course of their stay in hospital. Only M15 had high 
grade HE, and had very low mental capacity. M1 
received a liver transplant during the course of the study 
so his results show four pre-transplant samples and 
three post-transplant. Figure 5 shows concentrations 
of limonene, methanol and 2-pentanone in breath and 
room air over the course of the measurement period. 
For M1, study days 1, 2, 3 and 4 correspond to 47, 44, 42 
and 40 d prior to transplant, respectively. Study days 5, 6 
and 7 correspond to 28, 29 and 33 d after transplant. All 
measurements were taken in wards, except for study day 
7 which was taken in the out-patient clinic. For M15, 
Figure 4. Boxplots showing normalized counts per second lower quartile (LQ), median (Med) and upper quartile (UQ) calculated 
volume mixing ratios (VMRs) for m/z 89 for 11 patients without HE (No-HE), 8 patients who have a history of HE but are not 
showing symptoms on the day of sampling (history HCC), 12 patients who were suffering symptoms of HE on the day of sampling 
(HE-now), 30 controls and room air. Whiskers are 1.5 times the inter-quartile range and outliers are depicted by a star. Note that only 
18 room air samples are used as one sample gave a peak which could not be distinguished above the instrumental noise.
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if study day 1 is taken to be on day 1, study days 1–7 
correspond to days 1, 2, 6, 7, 8, 9 and 15. The patient was 
discharged on day 15.
The main thing to note is the high degree of 
 variability from day to day. Despite this, there is still a 
measureable drop in breath limonene and methanol 
following transplant for M1. There is what appears to be 
an anomalous result for 2-pentanone for M1 on study 
day 6, which is, at present, unexplained as it was also 
not present in the room air. A corresponding peak in 
the mass spectrum at m/z 89 suggests that it may have 
been a chlorinated compound. It is possible that the 
patient inhaled an environmental contaminant at high 
 concentration some time before the breath test and it 
was still washing out.
The variability for M15 is more pronounced than 
for M1. This patient had grade 3 or 4 HE for the first 6 d 
of the study. On study day 7 his acute HE had resolved 
sufficiently to be discharged later that day, although it 
is likely that he was still suffering from minimal HE as 
he had a recent history of repeated hospital admissions. 
There were difficulties in obtaining samples from this 
patient on some days of the study as his mental inca-
pacity was such that he was unable at times to comply 
with instructions to breathe into the apparatus. It was, 
therefore, very difficult to obtain reliable end-tidal 
Figure 5. Scatter plots showing in units of nmol mol−1 lower quartile (LQ), median (Med) and upper quartile (UQ) calculated 
volume mixing ratios (VMRs) for (a) limonene, (b) methanol and (c) 2-pentanone for patients M15 (left hand panel) and M1 
(right hand panel). Breath concentrations are shown in black triangles and room air in red triangles. For M1, study days 1–4 are 
pre-transplant and days 5–7 are post-transplant. For patient M15, all days are pre-transplant as he did not receive a transplant. The 
dashed horizontal line indicates the median of the concentration for healthy controls for each particular volatile. *The mean is given 
for M1 2-pentanone as it does not include the outlying point.
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samples and it is possible that some of his samples were 
contaminated with dead-space air. From this limited 
evidence, it does not appear that breath limonene can 
predict daily variations in symptoms of HE for an indi-
vidual patient.
4. Conclusions
Limonene, methanol and 2-pentanone have previously 
been shown to be elevated in the breath of cirrhotic 
patients compared with controls and in patients 
pre-transplant compared with the same patients 
after transplant [7]. Limonene, but not methanol or 
2-pentanone is able to discriminate patients currently 
suffering symptoms of HE from patients with no 
current symptoms. Patients with HCC had lower levels 
of limonene than those without HCC but this may be a 
reflection of the fact that patients with HCC are usually 
considered for transplant at an earlier stage of liver 
decompensation. This is supported by the fact that the 
UKELD scores for patients with HCC were significantly 
lower than patients without HCC.
It is possible that breath limonene is higher in more 
severe liver disease, and because HE is a complication 
of advanced disease, high breath limonene may simply 
be a proxy for advanced disease. However, there was no 
correlation between limonene and any clinical chem-
istry value. Nor was there a scorrelation with UKELD 
score. This leaves the possibility that limonene is itself a 
causative agent in HE. Limonene is highly lipophilic; this, 
together with its low molecular mass, make it possible 
for it to cross the blood–brain barrier. There have been 
cases of acute poisonings with tea tree oil, which is com-
posed of terpenes and terpinoids, including limonene 
at low levels. The symptoms were confusion, drowsi-
ness and coma [56]. These are strikingly similar to the 
symptoms of HE, and suggest that molecules from the 
oil crossed the blood–brain barrier to cause neurological 
symptoms. In all cases, the effects were transient and the 
patients recovered within a matter of hours. While this 
was not pure limonene, terpinoid oils are composed of 
similar units and it is not known what biochemical reac-
tions will occur if limonene is resident in the human body 
for long periods. While limonene has not been shown to 
be acutely toxic in humans [57], information is lacking 
about chronic exposure. If a cirrhosis patient lives with 
a high blood concentration of limonene for months or 
even years, it is not known how this will affect their health.
It has been shown that limonene concentrates in 
human breast tissue in women given a large daily dose 
of limonene for 2 weeks before undergoing surgery for 
breast cancer [58]. Breast tissue is composed mainly 
of fat [59] so this lends weight to our previously stated 
hypothesis [7] that limonene, being highly lipophilic, 
accumulates in the fat tissue of patients with liver dis-
ease. The wash-out curves for patients who gave breath 
samples on consecutive days in the 3 weeks after liver 
transplant presented in our previous paper [7] support 
this hypothesis. The brain has a high fat content, so it 
would be expected that limonene would partition into 
it should it cross the blood–brain barrier.
The main limitation of this study is the small sample 
size. The practical difficulty of requiring a patient with 
severe HE to comply with instructions would have to 
be addressed in future studies. The evidence presented 
here suggests that breath limonene is an exogenous 
compound which may serve as an indicator of an ele-
vated risk of HE in patients with cirrhosis of the liver. 
The hypothesis that limonene is itself in the causative 
pathway of HE remains to be explored.
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